Clorox Co Del SEC Filings

The Clorox Company (CLX) reported Q1 FY26 results with lower sales and earnings. Net sales were $1,429 million, down 19% year over year, as shipments normalized after ERP-related pull-forward in Q4 FY25. Gross profit was $596 million and gross margin declined to 41.7% from 45.8%, reflecting lower volume and higher manufacturing and logistics costs, partly offset by savings. Diluted EPS was $0.65 versus $0.80.

Operating cash flow was $93 million (vs. $221 million), driven by lower cash earnings and inventory, offset by lower receivables and higher payables. Current liabilities exceeded current assets by $539 million, primarily due to the upcoming cash purchase of P&G’s 20% Glad venture interest; the estimated fair value of that interest was $476 million, with $488 million recognized in accounts payable and accrued liabilities. Clorox cites expected operating cash flow, strong credit ratings, and available borrowing capacity to fund needs; its $1,200 million revolver was undrawn.

By segment, net sales declined: Health & Wellness $565 million (-19%), Household $362 million (-19%), Lifestyle $245 million (-23%), and International $253 million (-2%). The effective tax rate was 23.4% (vs. 41.8%). Dividends declared were $2.48 per share; share repurchases totaled $129 million.

The Clorox Company announced executive leadership changes. Eric Reynolds, Executive Vice President – Chief Operating and Strategy Officer, provided notice of his intention to resign after 27 years with the company. He will step down from his role effective December 2, 2025.

Reynolds will be available on an advisory basis as needed through February 2, 2026. The company stated it does not expect to appoint a replacement for Mr. Reynolds.

Insider transaction summary for CLOROX CO (CLX)

On 10/03/2025 Director and Chief Executive Officer Linda J. Rendle received 43,370 shares of common stock following settlement of a 2022 performance unit grant that vested on 10/03/2025. The shares were issued at an effective price of $122.25 per share. The filing shows share withholding to satisfy tax obligations: 1,022 shares withheld for performance stock unit taxes and 8,440 shares withheld for restricted stock taxes. After these transactions and including 4,274 dividend-reinvested shares, the reporting person beneficially owned 201,990 shares (direct).

Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co (CLX), reported changes in her beneficial ownership on 10/03/2025. She received 1,418 shares on settlement of a 2022 performance unit grant at a reported price of $122.25 per share and elected to defer settlement under the 2005 Stock Incentive Plan. The filing shows share withholding to cover tax obligations: 36 shares withheld for performance stock units and 243 shares withheld for restricted stock, both at $122.25. Following these transactions and including a 186-share dividend reinvestment, total beneficial ownership is reported as 7,271 shares (direct) before certain adjustments and 6,992 shares noted as indirect via a trust of a parent. The form is signed by an attorney-in-fact on 10/07/2025.

Insider stock settlement and tax withholdings recorded for CLOROX (CLX). On 10/03/2025 the reporting person received 6,812 common shares at $122.25 as the settlement of a 2022 performance unit award that vested and was elected for deferral under the company plan. The company withheld 162 shares and 948 shares to satisfy tax obligations for performance stock units and restricted stock, respectively. After these transactions the reported beneficial ownership declined to 35,133 shares, which includes 722 shares from dividend reinvestment.

Clorox (CLX) director and EVP Stacey Grier reported transactions dated 10/03/2025 showing settlement of a 2022 performance unit award and related share movements. The reporting person received 9,913 shares upon settlement of the performance unit grant, which she elected to defer under the 2005 Stock Incentive Plan. The company withheld 233 shares to cover taxes on performance stock units and 799 shares for taxes on restricted stock. After these transactions and including 1,004 dividend-reinvested shares, the filing shows beneficial ownership fell from 33,235 shares to 32,203.

Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on 10/03/2025 involving 15,489 shares issued upon settlement of a 2022 performance unit grant at an indicated price of $122.25 per share. The filing shows the company withheld 2,755 shares to satisfy tax obligations for restricted stock and 7,436 shares to satisfy tax obligations for performance stock units. After these transactions the reporting person beneficially owned 69,313 shares (including 739 dividend-reinvested shares).

Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25. The filing shows two share withholdings to satisfy tax obligations: 1,653 shares and 3,488 shares, each recorded at $122.25. Following these transactions the reporting person beneficially owns 38,280 shares (this total includes 534 shares from dividend reinvestment). The Form 4 was signed by an attorney-in-fact on 10/07/2025.